Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “TKI Resistance”

72 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 72 results

Testing effectiveness (Phase 2)Ended earlyNCT02495233
What this trial is testing

ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)

Who this might be right for
Non-Small-Cell Lung Cancer
Astellas Pharma Global Development, Inc. 10
Testing effectiveness (Phase 2)Study completedNCT03543683
What this trial is testing

Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC

Who this might be right for
Non-Small Cell Lung Cancer Stage IIIBNon-small Cell Lung Cancer Stage IVEGFR T790M
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 115
Not applicableUnknownNCT02988141
What this trial is testing

EGFR-TKI Resistance Profile in Chinese Patients With Advanced EGFRm+ NSCLC

Who this might be right for
Nonsmall Cell Lung Cancer
Jianxing He 100
Testing effectiveness (Phase 2)Looking for participantsNCT06277674
What this trial is testing

Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI

Who this might be right for
Non-small Cell Lung Cancer
Guangzhou University of Traditional Chinese Medicine 20
Testing effectiveness (Phase 2)Looking for participantsNCT06071013
What this trial is testing

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

Who this might be right for
Non-small Cell Lung CancerEGFR Gene MutationEGFR-TKI Resistant Mutation
China Medical University Hospital 20
Testing effectiveness (Phase 2)Ended earlyNCT02122003
What this trial is testing

Second Line Sorafenib After Pazopanib in Patients With RCC

Who this might be right for
Metastatic Renal Cell Carcinoma
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 16
Not applicableUnknownNCT01776684
What this trial is testing

Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis

Who this might be right for
EGFR Mutation Positive Non-small Cell Lung Cancer
Samsung Medical Center 200
Large-scale testing (Phase 3)UnknownNCT02972333
What this trial is testing

Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M

Who this might be right for
EGFR-TKI Resistant MutationNonsmall Cell Lung CancerAZD9291+1 more
Shandong Cancer Hospital and Institute 150
Testing effectiveness (Phase 2)Ended earlyNCT04971187
What this trial is testing

Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer

Who this might be right for
Locally Advanced Lung Non-Squamous Non-Small Cell CarcinomaMetastatic Lung Non-Squamous Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8+7 more
M.D. Anderson Cancer Center 3
Testing effectiveness (Phase 2)Study completedNCT01982955
What this trial is testing

Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)

Who this might be right for
Non-small Cell Lung Cancer
Merck KGaA, Darmstadt, Germany 88
Not applicableLooking for participantsNCT05598528
What this trial is testing

Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)

Who this might be right for
Lung Cancer, Non-small CellEGFR Gene MutationEGFR-TKI Resistant Mutation+2 more
Second Xiangya Hospital of Central South University 210
Testing effectiveness (Phase 2)Active Not RecruitingNCT03944772
What this trial is testing

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 247
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06818955
What this trial is testing

Orlistat Overcoming Third-generation EGFR-TKI Resistance

Who this might be right for
Lung AdenocarcinomaOsimertinib
Ping Peng 36
Not applicableUnknownNCT04116918
What this trial is testing

Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC

Who this might be right for
NSCLC Stage IVEGFR T790M-negativeAnlotinib+1 more
Baodong Qin 100
Not applicableUnknownNCT03532698
What this trial is testing

Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC)

Who this might be right for
Non-Small Cell Lung Cancer Stage IIIBNon-small Cell Lung Cancer Stage IVEGFR T790M
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 100
Testing effectiveness (Phase 2)Study completedNCT01262014
What this trial is testing

Clinical Trial Investigating Pazopanib in Patients With Platinum-resistant Advanced Ovarian Cancer

Who this might be right for
Platinum-resistant Advanced Ovarian Cancer
Grupo Español de Investigación en Cáncer de Ovario 28
Early research (Phase 1)Ended earlyNCT02468661
What this trial is testing

A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification

Who this might be right for
Non-Small Cell Lung Cancer
Novartis Pharmaceuticals 23
Testing effectiveness (Phase 2)Ended earlyNCT02025218
What this trial is testing

Iressa Re-challenge in Advanced NSCLC EGFR-mutated Patients

Who this might be right for
Lung Cancer
Amsterdam UMC, location VUmc 21
Testing effectiveness (Phase 2)UnknownNCT02139579
What this trial is testing

Efficacy and Safety Study of Bevacizumab Plus Chemotherapy in EGFR-TKI Resistant Non-Squamous Non-Small Cell Lung Cancer

Who this might be right for
Lung, Carcinoma
Sun Yat-sen University 24
Testing effectiveness (Phase 2)Study completedNCT02489903
What this trial is testing

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Who this might be right for
Small Cell CarcinomaCarcinoma, Non-Small-Cell LungNeuroendocrine Tumors+1 more
EpicentRx, Inc. 139
Load More Results